Free Trial

Arcus Biosciences (RCUS) Earnings Date, Estimates & Call Transcripts

Arcus Biosciences logo
$15.70 -0.07 (-0.44%)
(As of 11/15/2024 ET)

Arcus Biosciences Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 19Estimated
Actual EPS
(Nov. 6)
-$1.00 Beat By $0.06
Consensus EPS
(Nov. 6)
-$1.06

Arcus Biosciences issued Q3 2024 earnings on November 6, 2024, reporting an EPS of -$1.00, which beat analysts' consensus estimates of -$1.06 by $0.06. Quarterly revenue rose 50.0% year-over-year to $48 million, above the consensus estimate of $38.95 million. With a trailing EPS of -$3.15, Arcus Biosciences' earnings are expected to decrease next year, from ($3.20) to ($4.82) per share.

RCUS Upcoming Earnings

Arcus Biosciences' next earnings date is estimated for Wednesday, February 19, 2025, based off prior year's reporting schedules.

Get Arcus Biosciences Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcus Biosciences and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

RCUS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RCUS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arcus Biosciences Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.72-$0.72-$0.72
Q2 20241-$0.88-$0.88-$0.88
Q3 20243-$1.05-$0.70-$0.87
Q4 20243-$1.20-$0.72-$0.93
FY 20248-$3.85-$3.02-$3.40
Q1 20252-$0.89-$0.80-$0.85
Q2 20252-$0.88-$0.87-$0.88
Q3 20252-$0.97-$0.89-$0.93
Q4 20252-$0.95-$0.90-$0.93
FY 20258($3.69)($3.46)($3.58)

Arcus Biosciences Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/19/2025
(Estimated)
------- 
11/6/2024Q3 2024-$1.06-$1.00+$0.06-$1.00$38.95M$48.00M          
8/8/2024Q2 2024-$1.02-$1.02--$1.02$26.24M$39.00M        
5/8/2024Q1 2024-$0.97-$0.05+$0.92-$0.05$28.77M$145.00M        
2/21/2024Q4 2023-$1.09-$1.08+$0.01-$1.08$28.30M$31.00M        
11/7/2023Q3 2023-$1.12-$0.94+$0.18-$0.94$27.57M$32.00M        
8/7/2023Q2 2023-$1.10-$1.04+$0.06-$1.04$31.81M$29.00M    
5/9/2023Q1 2023-$1.06-$1.09 -$0.03-$1.09$22.47M$25.00M    
2/28/2023Q4 2022-$0.99-$0.93+$0.06-$0.93$23.43M$34.00M    

Arcus Biosciences Earnings - Frequently Asked Questions

Arcus Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 19th, 2025 based off last year's report dates. Learn more on RCUS's earnings history.

In the previous quarter, Arcus Biosciences (NYSE:RCUS) reported ($1.00) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.06) by $0.06. Learn more on analysts' earnings estimate vs. RCUS's actual earnings.

The conference call for Arcus Biosciences's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Arcus Biosciences's latest earnings report can be read online.
Read Transcript

Arcus Biosciences's earnings report can be found in their filing with the SEC.
View SEC filing

Arcus Biosciences (NYSE:RCUS) has a recorded annual revenue of $117 million.

Arcus Biosciences (NYSE:RCUS) has a recorded net income of -$307 million. RCUS has generated -$3.15 earnings per share over the last four quarters.

Arcus Biosciences's earnings are expected to decrease from ($3.20) per share to ($4.82) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NYSE:RCUS) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners